Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
It's not much of a rivalry yet.
Overview
Demand for GLP-1 drugs is soaring. Thanks to recent breakthroughs, medicines in this category are expanding their addressable markets and treating conditions such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatohepatitis, and others, in addition to diabetes and weight management, which are perhaps their most important areas.
Eli Lilly (NYSE: LLY) is a leader in this space, but several companies are looking to take its crown. One of them is Viking Therapeutics (NASDAQ: VKTX), a smaller biotech with promising GLP-1 candidates. Could Viking Therapeutics successfully challenge Eli Lilly? Let's find out which of these two stocks is a better buy for investors looking to capitalize on this opportunity.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.